1. Home
  2. SLN vs USNA Comparison

SLN vs USNA Comparison

Compare SLN & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$5.01

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

Logo USANA Health Sciences Inc.

USNA

USANA Health Sciences Inc.

HOLD

Current Price

$21.38

Market Cap

371.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
USNA
Founded
1994
1992
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.4M
371.5M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
SLN
USNA
Price
$5.01
$21.38
Analyst Decision
Buy
Hold
Analyst Count
6
1
Target Price
$39.67
$36.00
AVG Volume (30 Days)
355.5K
115.9K
Earning Date
02-26-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.90
Revenue
$25,830,000.00
$912,670,000.00
Revenue This Year
N/A
$10.42
Revenue Next Year
N/A
$3.37
P/E Ratio
N/A
$24.63
Revenue Growth
40.39
5.88
52 Week Low
$1.97
$18.48
52 Week High
$7.78
$38.32

Technical Indicators

Market Signals
Indicator
SLN
USNA
Relative Strength Index (RSI) 36.11 54.57
Support Level $4.88 $21.81
Resistance Level $6.13 $22.59
Average True Range (ATR) 0.51 0.86
MACD -0.04 0.11
Stochastic Oscillator 10.40 58.81

Price Performance

Historical Comparison
SLN
USNA

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

Share on Social Networks: